secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001628280-25-003387
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M
--------------------------------------------------------------------------------

- Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.
- Gross margin improved 7.8 points to 48.3% from 40.5% in prior year period.
- Net loss per share ($0.53) vs ($0.75) YoY; adjusted EBITDA ($16.3M) vs ($27.8M).
- FY2025 revenue guidance $372M-$379M; expects gross margin over 50% in Q4 FY2025.
- Cash and short-term investments $270.8M at Dec 31, 2024; shipped to ~2,376 customers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828025003387/0001628280-25-003387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828025003387/twist-20250203.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-003387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer